Cancer recurrence following immune-suppressive therapies in patients with immune-mediated diseases: a systematic review and meta-analysis
Background & Aims Physicians frequently encounter patients with immune-mediated
diseases and a history of malignancy. There are limited data on the safety of …
diseases and a history of malignancy. There are limited data on the safety of …
Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped
E Louis, JY Mary, G Vernier–Massouille, JC Grimaud… - Gastroenterology, 2012 - Elsevier
BACKGROUND & AIMS: It is important to determine whether infliximab therapy can be safely
interrupted in patients with Crohn's disease who have undergone a period of prolonged …
interrupted in patients with Crohn's disease who have undergone a period of prolonged …
Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial
D Laharie, A Bourreille, J Branche, M Allez, Y Bouhnik… - The Lancet, 2012 - thelancet.com
Background Ciclosporin and infliximab are potential rescue treatments to avoid colectomy in
patients with acute severe ulcerative colitis refractory to intravenous corticosteroids. We …
patients with acute severe ulcerative colitis refractory to intravenous corticosteroids. We …
Therapeutic drug monitoring of biologics during induction to prevent primary non-response
MP Sparrow, K Papamichael, MG Ward… - Journal of Crohn's …, 2020 - academic.oup.com
Biologic therapies have revolutionized the management of inflammatory bowel disease
[IBD], but primary and secondary non-responses occur in a significant proportion of patients …
[IBD], but primary and secondary non-responses occur in a significant proportion of patients …
Treatment algorithm for mild and moderate-to-severe ulcerative colitis: an update
E Burri, MH Maillard, AM Schoepfer, F Seibold… - Digestion, 2020 - karger.com
Background: Patient care in ulcerative colitis (UC) remains challenging despite an array of
established treatment options and emerging new therapies. The management of UC therapy …
established treatment options and emerging new therapies. The management of UC therapy …
Prevalence and factors associated with failure of liver stiffness measurement using FibroScan in a prospective study of 2114 examinations
J Foucher, L Castéra, PH Bernard… - European journal of …, 2006 - journals.lww.com
Liver stiffness measurement using FibroScan is a novel rapid and non-invasive technique
that evaluates liver fibrosis. In some cases, however, no elasticity measurement is obtained …
that evaluates liver fibrosis. In some cases, however, no elasticity measurement is obtained …
Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID …
P Marteau, M Lémann, P Seksik, D Laharie… - Gut, 2006 - gut.bmj.com
Background and aims: Early endoscopic recurrence is frequent after intestinal resection for
Crohn's disease. Bacteria are involved, and probiotics may modulate immune responses to …
Crohn's disease. Bacteria are involved, and probiotics may modulate immune responses to …
Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial
M LÉmann, JY Mary, B Duclos, M Veyrac, JL Dupas… - Gastroenterology, 2006 - Elsevier
Background & Aims: The aim of this study was to evaluate the usefulness of short-term
infliximab combined with azathioprine (AZA) or 6-mercaptopurine (6-MP) in steroid …
infliximab combined with azathioprine (AZA) or 6-mercaptopurine (6-MP) in steroid …
A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease
Background & Aims Tofacitinib, an orally administered Janus kinase inhibitor, blocks
signaling through γ-chain–containing cytokines (interleukins 2, 4, 7, 9, 15, and 21). We …
signaling through γ-chain–containing cytokines (interleukins 2, 4, 7, 9, 15, and 21). We …
Early administration of azathioprine vs conventional management of Crohn's disease: a randomized controlled trial
J Cosnes, A Bourrier, D Laharie, S Nahon, Y Bouhnik… - Gastroenterology, 2013 - Elsevier
Background & Aims Immunomodulator therapy is effective for patients with Crohn's disease
(CD) but has not been shown to affect disease progression, presumably because it is given …
(CD) but has not been shown to affect disease progression, presumably because it is given …